[Home](https://github.com/mm80843/T3.5/blob/main/docs/index.md) >> Class: [Risk](https://github.com/mm80843/T3.5/tree/main/docs/Risk/index.md) >> Individual ID:PBN__Risk_430 

# __Expectations for vaccine__

## Category to which it belongs

* [The challenges in vaccination include limited storage capacity, high patient demand, inefficient resource use, distribution difficulties, waning vaccine effectiveness, and unequal access.](https://github.com/mm80843/T3.5/blob/main/docs/PBNCategory/PBN__PBNCategory_113.md)

## Closest similar item

* [Inadequate vaccine efficacy](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_1911.md)
* [Demand for vaccine development](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_423.md)
* [Difficulty in vaccine distribution](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_519.md)
* [Vaccine availability, Vaccine hesitancy](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_3168.md)
* [Uncertainty of vaccine effectiveness, time-consuming research process](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_3080.md)
* [Waning efficacy of vaccines](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_861.md)
* [Vaccine hesitancy](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_1909.md)
* [Hesitation to vaccinate](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_2080.md)
* [Lack of vaccine or cure](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_1748.md)
* [High patient demand for vaccinations](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_155.md)

## Description of the risk

The development of effective vaccines against SARS-CoV-2 is a critical measure for long-term protection.

## Property: has_RiskGBN

* [No](https://github.com/mm80843/T3.5/blob/main/docs/RiskGBN/PBN__RiskGBN_0.md)

## Property: has_RiskHealth

* [physical](https://github.com/mm80843/T3.5/blob/main/docs/RiskHealth/PBN__RiskHealth_0.md)

## Property: has_RiskISO_Impact

* [Governance, empowerment and engagement](https://github.com/mm80843/T3.5/blob/main/docs/RiskISO/PBN__RiskISO_Purpose_6.md)

## Property: has_RiskISO_Purpose

* [Resilience](https://github.com/mm80843/T3.5/blob/main/docs/RiskISO/PBN__RiskISO_Impact_2.md)

## Mitigations of this risk

* [Vaccine development](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_598.md)
* [Continue research and development of vaccines against SARS-CoV-2.](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_3065.md)

## Name of the risk

Limited ability to prevent and control the spread of SARS-CoV-2 without effective vaccines.

## Stakeholders who can mitigate this risk

* [researchers](https://github.com/mm80843/T3.5/blob/main/docs/Stakeholder/PBN__Stakeholder_2.md)
* [scientists](https://github.com/mm80843/T3.5/blob/main/docs/Stakeholder/PBN__Stakeholder_46.md)
* [pharmaceutical companies](https://github.com/mm80843/T3.5/blob/main/docs/Stakeholder/PBN__Stakeholder_124.md)

## Articles mentionning the risk

* [Current knowledge of COVID-19: Advances, challenges and future perspectives](https://github.com/mm80843/T3.5/blob/main/docs/Article/PBN__Article_118.md)

## People affected by this risk

* [general population](https://github.com/mm80843/T3.5/blob/main/docs/Stakeholder/PBN__Stakeholder_9.md)
* [public health officials](https://github.com/mm80843/T3.5/blob/main/docs/Stakeholder/PBN__Stakeholder_310.md)

## Technologies linked to the risk

* [development of various vaccine strategies](https://github.com/mm80843/T3.5/blob/main/docs/Technology/PBN__Technology_1960.md)
* [clinical trials](https://github.com/mm80843/T3.5/blob/main/docs/Technology/PBN__Technology_1961.md)

## Property: has_RiskType

* [technological](https://github.com/mm80843/T3.5/blob/main/docs/RiskType/PBN__RiskType_5.md)

